In a nutshell This study examined if international prognostic scores (IPS) could help predict treatment outcomes for patients with advanced Hodgkin's lymphoma (HL). The authors found that the IPS system is losing its predictability as treatment strategies improve for these patients. Some background Patients with HL need to be treated...
Read MoreCurrent treatment status-Did not start treatment yet Posts on Medivizor
Valproate and retinoic acid with decitabine in elderly patients with acute myeloid leukemia
In a nutshell This study aimed to investigate the effects of valproate (Depakene) and all-trans retinoic acid (ATRA) in treatment-naive elderly patients with acute myeloid leukemia. This study concluded that the addition of ATRA to decitabine (Dacogen) chemotherapy led to a higher remission rate and survival...
Read MoreThe effect of fertility preservation on disease free survival in patients with invasive breast cancer
In a nutshell This study aimed to investigate if fertility preservation in patients with invasive breast cancer would affect disease-free survival. This study concluded that fertility preservation appears unlikely to affect disease-free survival in these patients. Some background Fertility preservation (FP) is the process of saving or...
Read MoreEvaluating subcutaneous rituximab for patients with non-Hodgkin lymphoma
In a nutshell This study examined whether it is safe to switch from intravenous to subcutaneous rituximab (Rituxan) during first-line treatment of non-Hodgkin's lymphoma (NHL). The authors concluded that subcutaneous rituximab was safe and effective, and improved quality of life for patients. Some background Rituximab is a standard...
Read MoreEvaluating intensive CVD chemotherapy for patients with multiple myeloma
In a nutshell This study examined if intensive chemotherapy after initial chemotherapy made treatment more effective for patients with multiple myeloma (MM). The authors concluded that intensive chemotherapy increased survival without tumor growth or spread for these patients. Some background In MM, cancer cells become different...
Read MoreIbrutinib, fludarabine, cyclophosphamide and rituximab for treating chronic lymphocytic leukemia
In a nutshell This study aimed to investigate the combination of ibrutinib with fludarabine, cyclophosphamide, and rituximab (FCR) as a frontline treatment in young, fit patients with chronic lymphocytic leukemia. This study concluded that this combination is promising as a...
Read MorePanitumumab improves the treatment outcomes of patients with advanced colorectal cancer
In a nutshell This study investigated the effectiveness of panitumumab (Vectibix) in the treatment of advanced colorectal cancer (CRC). Researchers suggested that this drug improved tumor response to the therapy. Some background CRC is one of the most common cancer worldwide. Chemotherapy such as FOLFOXIRI (leucovorin, fluorouracil, oxaliplatin,...
Read MoreEvaluating outcomes in patients with multiple myeloma after RVD therapy followed by stem cell transplant outside of clinical trials
In a nutshell This study assessed the safety and effectiveness of RVD (lenalidomide, bortezomib, dexamethasone) in patients with multiple myeloma before a stem cell transplant (SCT) in a real-life setting (outside of clinical trials). This study concluded that this treatment was safe and effective for these patients. Some background Multiple myeloma...
Read MoreCan FDG-PET/CT scanning predict treatment outcomes in diffuse large B-cell lymphoma?
In a nutshell This study evaluated whether FDG-PET/CT imaging during treatment helped predict outcomes for patients with diffuse large B-cell lymphoma (DLBCL). The authors concluded that mid-treatment imaging might help determine disease status rather than guide treatment decisions. Some background DLBCL is the most common type of...
Read MoreLooking for patients with metastatic triple-negative breast cancer to trial experimental vaccine with biological therapy
In a nutshell This trial is examining the most beneficial dose of an experimental AE37 vaccine when used with biological therapy pembrolizumab (Keytruda). The main outcomes to be measured are the maximum safest dose of AE37 and objective response rate. This study is recruiting in Illinois and West Virginia, US. The details Triple-negative...
Read MoreEvaluating the TLI-ATG conditioning regimen before allogeneic stem cell transplantation in patients with lymphoma or leukemia
In a nutshell This study evaluated the safety and effectiveness of total lymphoid irradiation and anti-thymocyte globulin (TLI-ATG) conditioning before stem cell transplantation (SCT) in patients with lymphoma or leukemia. This study concluded that this regimen was well-tolerated and effective, especially for patients who had multiple lines of prior...
Read MoreIbrutinib – rituximab vs chemoimmunotherapy for chronic lymphocytic leukemia
In a nutshell This study aimed to investigate the effectiveness of ibrutinib–rituximab treatment compared to standard chemoimmunotherapy in patients aged 70 or younger with previously untreated chronic lymphocytic leukemia (CLL). This study concluded that the ibrutinib–rituximab regimen provided...
Read More
